GE HealthCare Agreed to Buy Trilantic-Backed SOFIE Biosciences for $945 Million:

## KEY TAKEAWAYS - GE HealthCare has agreed to acquire Trilantic North America-backed SOFIE Biosciences, a U.S. PET radiopharmaceutical contract manufacturer, for $945 million in cash, with closing expected in H1 2027 pending regulatory approval. - SOFIE operates 15 U.S. contract manufacturing sites with 21 cyclotrons plus a theranostics development facility, providing critical "final mile" distribution capacity for short-lived fluorine-18 based imaging tracers that must be produced proximate to end-use hospitals and imaging centers. - The acquisition includes U.S. rights to FAPI-74, an experimental PET imaging agent in late-stage clinical development for cancer detection, complementing GE HealthCare's existing ex-U.S. rights to the asset. - The transaction represents a clean sponsor exit via cash sale to a large public medtech acquirer, providing certainty of proceeds and demonstrating sustained strategic value in radiopharmaceutical manufacturing and supply-chain assets. - Strategic buyers are increasingly targeting sponsor-owned contract manufacturers and specialty logistics providers in isotope production, as distributed manufacturing networks for short-lived radiopharmaceuticals remain difficult and capital-intensive to replicate. ## DETAILED SUMMARY Trilantic North America has completed a strategic exit from SOFIE Biosciences through a $945 million cash sale to GE HealthCare, announced on October 5, 2026. The transaction, expected to close in the first half of 2027 subject to regulatory clearance, will integrate SOFIE into GE HealthCare's pharmaceutical diagnostics division. The deal represents a clean sponsor liquidity event at a time when many private equity firms are increasingly reliant on continuation vehicles and secondary sales to return capital to investors. SOFIE's value proposition centers on its distributed manufacturing infrastructure—a network of 15 U.S. contract manufacturing sites operating 21 cyclotrons plus a theranostics-focused development and manufacturing facility. This footprint addresses a structural barrier in radiopharmaceutical supply: fluorine-18 based tracers have extremely short half-lives and must be manufactured in close proximity to the hospitals and imaging centers that use them, making large-scale centralized production economically inefficient and technically infeasible. Building an equivalent competing network would require substantial capital investment and regulatory navigation, creating durable competitive advantages that large medtech acquirers cannot easily replicate internally. Beyond manufacturing capacity, the acquisition includes U.S. commercialization rights to FAPI-74, an experimental PET imaging agent currently in late-stage clinical trials for cancer detection. GE HealthCare retains existing rights outside the United States, positioning the company to capture upside from the agent's potential regulatory approval and market adoption. Notably, SOFIE will continue manufacturing products for existing customers, including other radiopharmaceutical companies, post-closing—a structure that preserves SOFIE's contract manufacturing revenue while cementing GE HealthCare's control over critical imaging supply infrastructure. The transaction underscores a broader strategic thesis in healthcare investing: manufacturing and supply-chain assets, not solely drug pipelines, command premium valuations from large acquirers seeking to control production capacity for specialized, short-lived radiopharmaceuticals. Radiopharmaceuticals combine specialized infrastructure, regulatory barriers, and growing clinical demand as new imaging agents and targeted radiotherapies advance through development. These characteristics have made the sector persistently attractive to sponsors and are likely to sustain dealflow as strategic buyers increasingly recognize that distributed manufacturing networks in this space offer defensible competitive positions and margin expansion opportunities.